Therapeutic Response

HER2-negative and PD-L1 (CPS) >= 5 status confers therapeutic sensitivity to Capecitabine in combination with Nivolumab and Oxaliplatin in patients with Adenocarcinoma of the Gastroesophageal Junction.

Statements

Source and description